Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)’s share price traded down 6.3% during mid-day trading on Wednesday . The company traded as low as $1.00 and last traded at $1.04. 820,496 shares were traded during trading, an increase of 93% from the average session volume of 424,750 shares. The stock had previously closed at $1.11.

A number of equities research analysts have recently weighed in on BLPH shares. ValuEngine raised shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Monday, August 14th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Bellerophon Therapeutics in a report on Wednesday, September 6th.

The firm’s market cap is $36.93 million. The company’s 50 day moving average is $1.14 and its 200-day moving average is $1.29.

Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. On average, equities research analysts anticipate that Bellerophon Therapeutics, Inc. will post ($1.12) EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new position in Bellerophon Therapeutics in the second quarter valued at $1,316,000. Vanguard Group Inc. increased its stake in Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after purchasing an additional 211,111 shares during the period. Renaissance Technologies LLC increased its stake in Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after purchasing an additional 238,300 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new position in Bellerophon Therapeutics in the first quarter valued at $125,000. Institutional investors own 45.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/13/bellerophon-therapeutics-inc-blph-trading-down-6-3.html.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Receive News & Stock Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related stocks with our FREE daily email newsletter.